| Date | Title | Description |
| 21.06.2023 | Sequana Medical announces additional data on safety, quality of life and survival from North American pivotal alfapump® study (POSEIDON) | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces additional data on safety, quality of life and survi... |
| 16.06.2023 | Sequana Medical wins Best Technology Award for alfapump® at European Mediscience Awards | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that its alfapump has won the ‘Best Technology’ Awa... |
| 25.04.2023 | Sequana Medical successfully raises EUR 15.78 million in an Equity Placement | Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it successfully raised an ... |
| 09.02.2023 | Sequana Medical announces 2022 Full Year Results and 2023 Outlook | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces its financial results for the year ended 31 Decembe... |
| 08.02.2023 | Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces the successful completion of its GLP animal studies... |
| 05.02.2023 | JenaValve Appoints Dan Dearen to Board of Directors | JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has appointed Dan Dearen, medical device industry executive, to its Board of Directors.
... |
| 01.02.2023 | Sequana Medical announces grant of additional DSR® patent in United States | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces the grant of an additional US patent for its DSR (D... |
| 15.11.2022 | Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces positive top-line results from SAHAR... |
| 01.11.2022 | Sonendo® Announces Health Canada Regulatory Approval for Next Generation GentleWave® G4 System | Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it has received Health Canada regulatory approval for commercial sales of its recently announced GentleWave G4 Sys... |
| 25.10.2022 | Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON) | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces positive top-line results from the No... |
| 19.10.2022 | Sonendo, Inc. to Report Third Quarter 2022 Financial Results on November 9, 2022 | Sonendo, Inc. (“Sonendo”) (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the third quarter 2022 after the market close on Wednesday, Novem... |
| 18.10.2022 | Sonendo® Announces Next Generation GentleWave® G4 System | Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced the release of the GentleWave G4 System, the next generation of its innovative technology platform designed to treat to... |
| 23.09.2022 | Sonendo, Inc. Announces $63 Million Private Placement | Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced a private placement of common stock and pre-funded warrants, resulting in gross proceeds of $63 million. New and existi... |
| 14.09.2022 | JenaValve Completes Enrollment in the ALIGN-AR IDE Clinical Trial | JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the successful completion of patient enrollment in the ALIGN-AR Pivotal trial.
The ALIGN-AR tri... |
| 08.09.2022 | Sequana Medical announces H1 2022 results and provides business update | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces its business highlights and financia... |
| 31.08.2022 | JenaValve Raises $100 Million to Advance Trilogy TAVR Solution | JenaValve Technology, Inc. (“JenaValve or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that it has completed the initial closing of a $100 million Series... |
| 25.08.2022 | Alexandra Clyde appointed to Sequana Medical Board of Directors | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announces the appointment of Alexandra Clyde a... |
| 10.08.2022 | Sonendo, Inc. Reports Second Quarter 2022 Financial Results | Sonendo, Inc. (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter ended June 30, 2022.
Recent Highlights
Total revenue of $10.5 million for the second ... |
| 20.07.2022 | Sequana Medical secures EUR 10 million loan facility with Kreos Capital | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces it has entered into a secured loan facility ... |
| 19.07.2022 | Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, today announces the completion of enrollment in its Phase 2a... |
| 05.07.2022 | Sonendo, Inc. Welcomes Joanne Lindberg as Vice President of Sales, North America | Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced the appointment of Joanne Lindberg as Vice President of Sales, North America. As Sonendo continues to scale and further... |
| 28.06.2022 | Results of First Commercial Trilogy Heart Valve System Implants in EU | JenaValve Technology, Inc. (“JenaValve” or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, announced positive results from the first Trilogy Heart Valve System commercial i... |
| 17.06.2022 | Sonendo, Inc. Announces Executive Management Team Changes | Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced two upcoming departures from its executive management team. Jacqueline Collins, vice president, general counsel, and Me... |
| 17.05.2022 | JenaValve Appoints Kari Moore as Chief Financial Officer | JenaValve Technology, Inc. (“JenaValveor the “Company”), developer and manufacturer of differentiated transcatheter aortic valvereplacement (TAVR) systems, today announced the appointment of Kari Moore as theCompany’s CFO effective May 10th... |
| 10.05.2022 | Sonendo, Inc. Reports First Quarter 2022 Financial Results | Sonendo, Inc. (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter ended March 31, 2022.
Recent Highlights
Total revenue of $9.0 million for the first q... |
| 20.04.2022 | Sonendo Announces Launch of CleanFlow Technology to Improve Doctor and Patient Experience | Sonendo, Inc. (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced the launch of its CleanFlow™ procedure instrument, which is designed to work with Sonendo’s GentleWave System to provid... |
| 05.04.2022 | Sequana Medical announces the completion of alfapump® implantations in POSEIDON, the North American pivotal alfapump study | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites, and heart failure, today announces that it has compl... |
| 23.03.2022 | Sonendo Inc. Reports Fourth Quarter 2021 Financial Results and Issues Full Year 2022 Revenue Guidance | Sonendo, Inc. (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter and year ended December 31, 2021.
Recent Highlights
“We are very pleased with our qua... |
| 15.03.2022 | Sonendo, Inc. Hits New Milestone of 800,000 GentleWave® Procedures, Demonstrating Continued Adoption and Growing Preference for Less Invasive Alternative to Traditional Root Canal Therapy | Sonendo, Inc. (NYSE: SONX), a dental technology company and creator of the GentleWave System for less invasive and less painful root canal therapy, today announced its achievement of a new milestone of 800,000 GentleWave patient procedures.... |
| 10.03.2022 | Sequana Medical announces new Share Capital Amount and New Number of Shares | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces that in the context of t... |
| 02.03.2022 | Sonendo, Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 23, 2022 | Sonendo, Inc. (“Sonendo”) (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the fourth quarter and full year 2021 after the market close on W... |
| 14.02.2022 | Sequana Medical receives certification under MDR, the new European Medical Device Regulation | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces it has received Med... |
| 18.01.2022 | JenaValve Announces Strategic Investment and Licensing Agreement with Peijia Medical Limited | JenaValve Technology, Inc. (“JenaValve” or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced a strategic investment and exclusive technology licensing agreeme... |
| 14.01.2022 | Sonendo, Inc. Announces Preliminary Revenue Results for the Fourth Quarter and Full-Year 2021 | Sonendo, Inc. (“Sonendo”) (NYSE: SONX), a leading dental technology company and developer of the GentleWave® System, today announced certain unaudited preliminary revenue results for the fourth quarter and full-year ended December 31, 2021.... |
| 09.12.2021 | Sonendo Inc. Reports Third Quarter 2021 Financial Results and Issues Full Year 2021 Revenue Guidance | Sonendo, Inc. (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the quarter ended September 30, 2021.
Recent Highlights
“We are very pleased with our quarterly r... |
| 07.12.2021 | Sequana Medical announces positive interim results of SAHARA DESERT, the alfapump DSR® study in heart failure patients with persistent congestion | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or Sequana Medical), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive interim resu... |
| 06.12.2021 | Sequana Medical announces the completion of patient enrolment in POSEIDON, the North American pivotal alfapump® study | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces the completion of p... |
| 10.11.2021 | Sonendo's GentleWave Surpasses 700,000 Treatments, Solidifying Procedure as Alternative to Traditional Root Canal Therapy | Sonendo, Inc., (NYSE: SONX) a leading dental technology company and developer of the GentleWave® System, today announced it has treated over 700,000 patients with its GentleWave® System, an alternative to traditional root canal therapy (RCT... |
| 28.10.2021 | Sonendo, Inc. Announces Pricing of Initial Public Offering | Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, today announced the pricing of its initial public offering of 7,800,000 shares of its common stock at a public offering price of $12.00 per share, f... |
| 25.10.2021 | Sonendo, Inc. Announces Launch of Initial Public Offering | Sonendo, Inc. (“Sonendo”), a leading dental technology company and developer of the GentleWave® System, today announced that it has launched the roadshow for its initial public offering of shares of its common stock. Sonendo is offering 7,8... |
| 18.10.2021 | Immunocore and Medison Pharma Partner for Future Commercialization of Tebentafusp in Canada, Central Eastern Europe, and Israel | Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoi... |
| 14.10.2021 | JenaValve Announces First European Commercial Implants with the Trilogy Heart Valve System | JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the first commercial implants with the Trilogy Heart Valve System in Europe. The procedures, whi... |
| 08.10.2021 | Sonendo®, Inc. Announces Filing of Registration Statement for Proposed Initial Public Offering | Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to... |
| 05.10.2021 | Sonendo® Acquires Portfolio of Novel Dental Procedure Technology Patents | On October 5, 2021, Sonendo, Inc., announced its acquisition of all assets of Israeli dental company FluidFile Ltd. These assets primarily consist of a patent portfolio of 24 granted patents and pending patent applications with global reach... |
| 04.10.2021 | Sequana Medical announces FDA approval to expand patient enrolment in North American pivotal alfapump® study (POSEIDON) | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that is has received approval from the U... |
| 16.09.2021 | Repligen Announces Agreement to Acquire Avitide Inc. | Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Avitide Inc., for approximately $150 milli... |
| 08.09.2021 | Immunocore Announces UKs Medicines and Healthcare Products Regulatory Agency (MHRA) Accepts Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma | Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and auto... |
| 02.09.2021 | Sequana Medical announces H1 2021 results and provides business update | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces its business highlights and financial re... |
| 31.08.2021 | Sequana Medical appoints Jackie Fielding, former Medtronic VP, to its Board of Directors | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that it has appointed Jackie Fielding, a... |
| 24.08.2021 | Food and Drug Administration and European Medicines Agency accept Biologics License Application and Marketing Authorization Application for Tebentafusp in Metastatic Uveal Melanoma | Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infect... |
| 16.08.2021 | JenaValve Receives IDE Approval to Initiate The ALIGN-AR Pivotal PMA Trial | JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced FDA approval for the company to initiate its Investigational Device Exemption (IDE) PMA clinica... |
| 11.08.2021 | Immunocore Reports Second Quarter 2021 Financial Results and Provides Business Update | Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infect... |
| 06.07.2021 | Sequana Medicals results from RED DESERT alfapump DSR® study presented as one of the Highlights at Heart Failure 2021 Online Congress | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the positive r... |
| 01.07.2021 | Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump® study (POSEIDON) | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive results fr... |
| 04.06.2021 | Immunocore presents clinical data further characterizing the overall survival benefit of tebentafusp in metastatic uveal melanoma | Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoi... |
| 01.06.2021 | Sequana Medical announces first patient enrolled in SAHARA DESERT | Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the first patient has been enrolled in the SAHARA ... |
| 25.05.2021 | JenaValve Technology Receives CE Mark for its TrilogyTM TAVI System for the Treatment of Aortic Regurgitation and Aortic Stenosis | JenaValve Technology, Inc., developer, and manufacturer of differentiated transcatheter aortic valve implantation (TAVI) systems (also referred to as TAVR, or transcatheter aortic valve replacement) for the treatment of aortic valve disease... |
| 20.05.2021 | Axonics® Receives FDA Approval Further Expanding MRI Labeling | Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has received FDA approval allowing the use of detachable extremity c... |
| 18.05.2021 | Immunocore announces dosing of first patient with ImmTAV® bispecific molecule for chronic Hepatitis B | Immunocore Holdings Plc (Nasdaq: IMCR) (or the “Company”), a pioneering, clinical‐stage T cell receptor biotechnology company working to develop and commercialise a new generation of transformative medicines to address unmet needs in cancer... |
| 18.05.2021 | Axonics® Announces CE Mark Approval for Implantable Sacral Neurostimulator that Significantly Extends Recharge Interval | Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced European CE Mark approval of its second generation A... |
| 14.05.2021 | Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters Option to Purchase Additional Stock | Axonics, Inc. (Nasdaq: AXNX), (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 4... |
| 12.05.2021 | Immunocore Reports First Quarter 2021 Financial Results | Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infect... |
| 11.05.2021 | Axonics® Announces Upsize and Pricing of Public Offering of Common Stock | Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the pricing of its public offering of... |
| 11.05.2021 | Sequana Medical announces strong top-line results from RED DESERT alfapump DSR® study and expansion of DSR® development programme | Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces positive top-line results from the RED DESERT study wit... |
| 06.05.2021 | Axonics® Reports First Quarter 2021 Financial Results | Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the first quarter ended March 3... |
| 12.04.2021 | Immunocore presents phase 3 data comparing tebentafusp with investigators choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting | Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and auto... |
| 25.03.2021 | Immunocore Provides Business Update and Reports Full Year 2020 Financial Results | Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and auto... |
| 17.03.2021 | Sequana Medical announces 2020 Full Year Results and 2021 Outlook | Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces its financial results for the year ended... |
| 02.03.2021 | Axonics® Announces Strategic Alliance for the Manufacture of New Non-Rechargeable Implantable Sacral Neuromodulation Device | Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced it has entered into a str... |
| 01.03.2021 | Oxular raises $37 million | Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announced that it has completed a $37 million (£27 million) financing led by Forbion. Proceeds will fund planned further clinical development of its lead a... |
| 25.02.2021 | Axonics® Expands into Stress Urinary Incontinence with the Acquisition of Bulkamid® | Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today an... |
| 25.02.2021 | Axonics® Reports Fourth Quarter and Fiscal Year 2020 Results | Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today re... |
| 19.02.2021 | Immunocores tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA | Immunocore (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and auto... |
| 09.02.2021 | Immunocore Announces Closing of $312.1 Million Financing | Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infect... |
| 09.02.2021 | Immunocore Announces Closing of $312.1 Million Aggregate Financing, Consisting of $297 | Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infect... |
| 08.02.2021 | Dr. Jatinder Kapur appointed as VP of Quality | Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces that it has appointed Dr. Jatinder Kapur as Vice President of Quality.
His primary responsibilities include establishing and managing the Compan... |
| 05.02.2021 | Immunocore Announces Pricing of Upsized Initial Public Offering | Immunocore Holdings plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infect... |
| 04.02.2021 | Sequana Medical announces granting of key alfapump DSR® patents in U.S. and Europe | Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces the granting of key patents for the alfapump DSR (Direc... |
| 25.01.2021 | Axonics® Reports Preliminary Fourth Quarter and Fiscal Year 2020 Revenue | Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today re... |
| 11.01.2021 | Immunocore announces closing of $75.0 Million Series C round | Immunocore, a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease,... |
| 16.12.2020 | Sonendo® Launches 500K Club Charitable Initiative | Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, announced today the launch of its “500K Club” to celebrate the company’s recently announced achievement of having more than 500,000 patients treated... |
| 08.12.2020 | Sonendo® Reaches 500,000 Patients Treated Milestone with the GentleWave® Procedure | Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, today announced that more than 500,000 patients have been treated with the GentleWave Procedure.
Sonendo’s GentleWave System ushers in the next evo... |
| 03.12.2020 | Immunocore presents Phase 2 tebentafusp clinical results at ESMO Immuno-Oncology Virtual Congress 2020 | Immunocore (or the “Company”), a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infection and autoimmune disease,... |
| 23.11.2020 | Immunocores tebentafusp demonstrates superior overall survival compared to investigators choice in a Phase 3 clinical trial of patients with previously untreated metastatic uveal melanoma | Immunocore (the “Company”), a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune, today ann... |
| 19.11.2020 | Sequana Medical announces positive interim data from North American pivotal alfapump® study (POSEIDON) | Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces positive interim results from the first 13 patients in the Roll-In Cohort... |
| 03.11.2020 | Genkyotex announces the closing of the acquisition by Calliditas Therapeutics of a controlling interest in Genkyotex | Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announced the closing of the acquisition by Calliditas Therapeutics AB (“Calliditas”; Nasdaq OMX – CALTX; NASDAQ - ... |
| 22.10.2020 | Sequana Medical announces strong interim results from RED DESERT alfapump® DSR study and provides business update | Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces positive interim results from the first five patients enrolled in the RED... |
| 20.10.2020 | Axonics® Launches ARTISTRY Study to Collect and Analyze Real-World Data of Patients Implanted with the Axonics r-SNM System | Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has laun... |
| 20.10.2020 | Genkyotexs setanaxib granted Orphan Drug Designation by the US FDA for the treatment of PBC | Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and leader in NOX therapies, today announced that its lead drug candidate, setanaxib, has been granted orphan drug designation (ODD) by the US Food ... |
| 08.10.2020 | X4 Pharmaceuticals Announces Fast Track Designation Granted by the FDA to Mavorixafor for the Treatment of WHIM Syndrome | X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that the U.S. Food and Drug Administration (FDA) has g... |
| 07.10.2020 | Axonics® CEO Raymond W. Cohen Named Ernst & Young Entrepreneur of the Year® 2020 Award Winner for Orange County | Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, today announce... |
| 05.10.2020 | Axonics® Announces Survey Results of Patients Treated with the Axonics r-SNM System That Were Previously Implanted with InterStim II | Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today an... |
| 24.09.2020 | Axonics® Provides Update on Inter Partes Review Proceedings | Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today an... |
| 21.09.2020 | Axonics® Receives Health Canada Approval of Next Generation Implantable Neurostimulator | Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, today announce... |
| 17.09.2020 | Genkyotex announces first-half 2020 results and business update | Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and leader in NOX therapies, today provides business update and announces its consolidated financial results for the six months ended June 30, 2020,... |
| 16.09.2020 | Axonics® CEO Raymond W. Cohen Named Ernst & Young Entrepreneur of the Year® 2020 Award Finalist for Orange County | Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation devices for the treatment of urinary and bowel dysfunction, today announce... |
| 14.09.2020 | Genkyotex announces the enrollment of the 1st patient in the Phase 2 trial of setanaxib in idiopathic pulmonary fibrosis (IPF) | Genkyotex (Euronext Paris & Brussels: FR0013399474 – GKTX), a biopharmaceutical company and leader in NOX therapies, today announced the enrollment of the first patient in the investigator-initiated Phase 2 clinical trial of setanaxib, ... |
| 10.09.2020 | Axonics® Reports 2-Year Clinical Results from ARTISAN-SNM Pivotal Study | Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has repo... |
| 08.09.2020 | NICE Recommends Axonics® r-SNM System for Treating Overactive Bladder | Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today an... |
| 03.09.2020 | Sequana Medical announces H1 2020 results and provides business update | Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces its business highlights and financia... |
